P2Y12 Polymorphisms and the Risk of Adverse Clinical Events in Patients Treated with Clopidogrel: A Meta-Analysis

Authors

Kun Zhao^{1, 2*}, Ming Yang^{3*}, Yanxia Lu⁴, Shusen Sun⁵, Wei Li⁶, Xingang Li^{1, 6}, Zhigang Zhao^{1, 6}

Affiliations

- 1 Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China
- 2 Department of Pharmacy, Beijing Friendship Hospital Pinggu Campus, Capital Medical University, Beijing, People's Republic of China
- 3 Department of Anesthesiology, Tianjin Eye Hospital, Tianjin, People's Republic of China
- 4 Department of Pharmacy, The General Hospital of the Chinese People's Armed Police Forces, Beijing, People's Republic of China
- 5 College of Pharmacy and Health Sciences, Western New England University, Springfield, Massachusetts, United States of America
- 6 Monogenic Disease Research Center for Neurological Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China

Key words

Clopidogrel, adverse clinical events, P2Y12 polymorphism, meta-analysis

received 24.02.2018 accepted 25.04.2018

Bibliography

DOI https://doi.org/10.1055/a-0622-8110 Published online: 23.5.2018 Drug Res 2019; 69: 23–31 © Georg Thieme Verlag KG Stuttgart · New York ISSN 2194-9379

Correspondence

Xingang Li Department of Pharmacy Beijing Tiantan Hospital Capital Medical University No. 6 TiantanXili, Dongcheng District 100050 Beijing China Tel.: + 86/010/67096 857, Fax: + 86/010/67096 867 Ixg198320022003@163.com Zhigang Zhao Department of Pharmacy Beijing Tiantan Hospital Capital Medical University No. 6 TiantanXili, Dongcheng District 100050 Beijing China Tel.: + 86/010/67098 036, Fax: + 86/010/67096 867 1022zzg@sina.com

Supporting Information for this article is available online at http://www.thieme-connect.de/products

ABSTRACT

Background and study aim Some studies have reported an association between P2Y12 gene polymorphisms and clopidogrel adverse outcomes with inconsistent results. We aimed to explore the relationship between P2Y12 polymorphisms and the risk of adverse clinical events in patients treated with clopidogrel through a meta-analysis.

Methods A systematic search of PubMed, Web of Science and the Cochrane Library was conducted. Retrieved articles were comprehensively reviewed and eligible studies were included, and the relevant data was extracted for this meta-analysis. All statistical tests were performed by the Review Manager 5.3 software.

Results A total of 14 studies involving 8,698 patients were included. In the Han Chinese population, ischemic events were associated with P2Y12 T744C polymorphism in the CC vs TT + CT genetic model (OR = 3.32, 95 %CI = 1.62-6.82, P=0.001), and the events were associated with P2Y12 C34T polymorphism in the TT + TC vs CC genetic model (OR = 1.70, 95 %CI = 1.22-2.36, P = 0.002). However, ischemic events were not related to P2Y12 G52T polymorphism (TT + TG vs GG: OR = 1.13, 95 %CI = 0.76-1.68, P = 0.56; TT vs GG + TG: OR = 2.02, 95 %CI = 0.65-6.28, P = 0.22). The associations between the P2Y12 polymorphism and ischemic events were not significant in T744C, G52T and C34T genotype for another subgroup of the Caucasian population (P>0.05). Only two studies referring to bleeding events were included in this analysis of C34T polymorphism, and no significant association was found (TT + TC vs CC: OR = 1.07, 95 %CI = 0.37-3.15, P = 0.90). **Conclusions** In the Caucasian population, P2Y12 gene polymorphisms are not associated with clinical events. However, in the Chinese Han population, P2Y12 T744C and C34T polymorphisms are significantly associated with adverse clinical events.

Kun Zhao and Ming Yang contributed equally to this work and should be considered as co-first authors.

Introduction

Clopidogrel is an important antiplatelet drug, inhibiting the adenosine diphosphate (ADP)-induced platelet aggregation. Aspirin plus clopidogrel are recommended for the treatment and prevention of cerebrovascular and cardiovascular diseases[1]. Clopidogrel has been widely used for ischemic stroke (IS) and acute coronary syndrome (ACS), particularly in patients undergoing percutaneous coronary intervention (PCI)[2]. However, some patients still have adverse clinical outcomes with clopidogrel treatment, including composite ischemic events [transient ischemic attack (TIA), myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis (ST), vascular-related mortality, etc.] and bleeding events[3–5].

Genetic polymorphisms play a vital role in the clopidogrel response variability[6]. Clopidogrel inhibits the platelet P2Y12 (purinergic receptor P2Y, G-protein coupled, 12) receptor, and the receptor gene polymorphisms may be an important factor in the drug response. T744C (rs2046934), G52T (rs6809699) and C34T (rs6785930) polymorphisms have been reported frequently for the association of the P2Y12 receptor gene and adverse clinical events. Haplotype (H1/H2) could be generated by the C139T, T744C, ins801A and G52T polymorphisms, as the four single nucleotide polymorphisms (SNPs) are in complete linkage disequilibrium. The C34T polymorphism is not linked to the four SNPs[7].

A number of studies have reported the association of P2Y12 gene polymorphisms with clopidogrel adverse clinical events. For T744C, Li XQ considered that the T allele was associated with an increased risk of major adverse cardiac events[8]. While Sun B showed that the impact of T744C polymorphism on the recurrence of ischemic events was not significant[9]. Studies of other mutation alleles had similarly inconsistent results. This led us to conduct a meta-analysis of the published studies, and we aimed to systematically identify the association of P2Y12 gene polymorphisms with the risk of adverse clinical events in clopidogrel treated patients.

Materials and Methods

Literature search

The electronic databases of PubMed, Web of Science and the Cochrane Library were searched. Search terms were "P2RY12 OR P2Y12" AND "clopidogrel OR antiplatelet OR platelet" AND "single nucleotide polymorphisms OR SNP OR polymorphism OR variant OR variation". All eligible studies were retrieved by full texts on March 23, 2018. The bibliographies of the included articles were searched to identify other pertinent articles.

Inclusion and exclusion criteria

The inclusion criteria were: (1) published in English, (2) case-control studies, (3) patients with cardiovascular or cerebrovascular diseases, (4) patients receiving a maintenance dose 75 mg/day of clopidogrel and (5) with complete data about P2Y12 genotyping and adverse clinical events. Animal trials, case reports, reviews, studies with incomplete data about P2Y12 gene and adverse clinical events, conference papers, and studies with a follow-up < 3 months were excluded.

Data extraction

Two reviewers independently screened all retrieved studies by titles and abstracts, and then by the full texts. Eligible studies were obtained by using the inclusion and exclusion criteria. Any disagreements were resolved by discussion. Standardized forms were used for data extraction, including the first author of a study, publication year, country, race, studied population, treatment protocol, sample size, P2Y12 genotype, follow-up time, and all adverse clinical outcomes. The Newcastle-Ottawa Scale (NOS) was used for assessing the quality of the included studies[10].

Statistical analysis

All statistical tests for this meta-analysis were performed by the Review Manager 5.3 (The Cochrane Collaboration, Oxford, UK). The odds ratio (OR) with 95 % confidence interval (CI) was used to assess the strength of the association between P2Y12 polymorphisms and adverse clinical events in clopidogrel-treated patients. The test for heterogeneity was performed for each meta-analysis. The fixed-effects model (FE) was adopted if there was no statistical difference (P>0.1, I² < 50 %), otherwise the random-effects model (RE) was chosen[11]. Sensitivity analyses were conducted by an individual exclusion of each study to assess its effect on the pooled outcome OR[12]. The publication bias was assessed by the funnel plot. P<0.05 indicates a significant difference among different genotypes[13].

Results

Study characteristics

A total of 668 articles were identified through database searching, of which 210 duplicate articles were excluded. Additionally, 434 articles (238 irrelevant studies, 119 reviews, 8 conference papers, 59 studies without adverse events, 4 animal trials, 4 case reports, and 2 non-English-language study) were excluded by title and abstract screening. Then, six studies[14–18] with incomplete data, one study[19] with incorrect data, one study[20] with a followup < 3 months and one study [21] without full-text were excluded respectively. Fifteen studies[8,9,22-34] met the inclusion criteria. However, one study [26] was not included, because the genotypes of all recruited population were of homozygous wild-type (GG). A total of 14 studies were included in this meta-analysis (Supporting Material 1), including 8,698 patients. All patients received aspirin in these studies with pre-specified ischemic or bleeding events. The NOS value of each article is greater than 5. The baseline characteristics (race, patient population, treatment protocol, sample size, genetic locus, follow-up period, outcomes, NOS score etc.) of the studies are presented in the Supporting Material 2.

Meta-analysis results

Association of the P2Y12 T744C polymorphism with ischemic events.

Eight of the fourteen included studies reported an association between the P2Y12 T744C polymorphism and adverse clinical events in clopidogrel-treated patients. In the CC + CT vs TT genetic model, a total of 4,348 patients were enrolled: 435 had ischemic events and 1,329 were carriers of the C allele. In another genetic model (CC vs

	CC+C		TT			Odds Ratio	Odds Ratio	
Study or Subgroup	Events	rotal	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl	
.1.1 Han Chinese	40	00	40	400	44.00/	4 00 10 00 0 701		
.i XQ 2016	19	98	19	166	14.3%	1.86 [0.93, 3.72]		
Du W 2016	11	31	29	63	11.0%	0.64 [0.27, 1.57]		
Sun B 2015	8	32	23	86	10.4%	0.91 [0.36, 2.32]] _	
Vang XD 2016	19	126	12	210	13.1%	2.93 [1.37, 6.26]		
(ang HH 2016	15	94	5	84 609	8.8%	3.00 [1.04, 8.65]		
Subtotal (95% CI)	70	381		009	57.7%	1.59 [0.88, 2.84]		
Total events	72		88		2 530/			
leterogeneity: Tau ² = 0.2			= 4 (P =	0.05); I	2 = 57%			
Test for overall effect: Z =	= 1.55 (P =	0.12)						
.1.2 Caucasian								
Malek LA 2008	0	24	6	81	1.6%	0.24 [0.01, 4.36]		
Rudez G 2008	56	693		1199	22.2%	0.94 [0.67, 1.31]		
/iviani Anselmi C 2013	21	231		1130	18.5%	1.17 [0.71, 1.92]	- =	
Subtotal (95% CI)		948		2410	42.3%	0.99 [0.75, 1.31]	•	
Total events	77		198					
Heterogeneity: Tau ² = 0.0		47. df		0.48): 1	$^{2} = 0\%$			
Test for overall effect: Z =			- (,, .	0,0			
		,						
fotal (95% CI)		1329		3019	100.0%	1.30 [0.88, 1.90]	◆	
Total events	149		286					
leterogeneity: Tau ² = 0.1	14; Chi ² = 1	5.18, c	if = 7 (P =	= 0.03);	l² = 54%			
iotorogonony. ruu or								
Test for overall effect: Z =	= 1.32 (P =	0.19)				0.	.01 0.1 1 10	
0 ,	•	,	df = 1 (P	= 0.15). I² = 50.6		.01 0.1 1 10 Favours [experimental] Favours [cont	
Test for overall effect: Z =	•	,	df = 1 (P	= 0.15). I² = 50.6			
Fest for overall effect: Z = Fest for subaroup differer	•	,	df = 1 (P TT+). I² = 50.6			
Test for overall effect: Z =	nces: Chi² : CC	= 2.03.	TT+	ст		%	Favours [experimental] Favours [cont	
Fest for overall effect: Z = Fest for subaroup differer	nces: Chi² : CC	= 2.03.	TT+	ст		% Odds Ratio	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subaroup differer	nces: Chi² : CC	= 2.03.	TT+	CT <u>5 Tota</u>	l Weight	% Odds Ratio M-H. Fixed. 95% Cl	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subaroup differer Study or Subgroup I.2.1 Han Chinese	nces: Chi ² : CC <u>Events</u>	= 2.03. Total	TT+ Events	СТ <u>5 Tota</u> 5 258	l Weight 3 4.2%	% Odds Ratio <u>M-H. Fixed. 95% Cl</u> 6.37 [1.24, 32.83]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subaroup differer Study or Subgroup I.2.1 Han Chinese Li XQ 2016	nces: Chi ² : CC <u>Events</u> 3	= 2.03. <u>Total</u> 6	TT+ Events	CT <u>Tota</u> 258 90	1 Weight 3 4.2% 0 4.2%	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subaroup differer Study or Subgroup I.2.1 Han Chinese Li XQ 2016 Du W 2016	nces: Chi ² : CC <u>Events</u> 3 3	= 2.03. <u>Total</u> 6 4	TT+ <u>Events</u> 35 37	CT Tota 258 90 113	Weight 3 4.2% 3 4.2% 3 10.8%	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subaroup differer Study or Subgroup I.2.1 Han Chinese Li XQ 2016 Du W 2016 Sun B 2015	CC Events 3 3 1	= 2.03. <u>Total</u> 6 4 5	TT+ Events 35 37 30	CT Tota 258 90 113	Weight 4.2% 4.2% 10.8% 11.7%	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup differer 2.2.1 Han Chinese Li XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016	CC Events 3 3 1	= 2.03. <u>Total</u> 6 4 5 36	TT+ Events 35 37 30	CT 5 Tota 5 258 5 90 113 142 603	Weight 4.2% 4.2% 10.8% 11.7%	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup I.2.1 Han Chinese I. XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Fotal events	nces: Chi ² : CC <u>Events</u> 3 3 1 9 16	= 2.03. <u>Total</u> 6 4 5 36 51	TT+ Events 35 37 30 11 113	CT <u>5 Tota</u> 5 258 5 90 113 142 603	Weight 4.2% 4.2% 10.8% 11.7%	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup 1.2.1 Han Chinese Li XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI)	CC Events 3 3 1 9 16 58, df = 3 (1	= 2.03. <u>Total</u> 6 4 5 36 51 P = 0.4	TT+ Events 35 37 30 11 113 113 (4); I ² = 0	CT <u>5 Tota</u> 5 258 5 90 113 142 603	Weight 4.2% 4.2% 10.8% 11.7%	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup 1.2.1 Han Chinese Li XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z =	CC Events 3 3 1 9 16 58, df = 3 (1	= 2.03. <u>Total</u> 6 4 5 36 51 P = 0.4	TT+ Events 35 37 30 11 113 113 (4); I ² = 0	CT <u>5 Tota</u> 5 258 5 90 113 142 603	Weight 4.2% 4.2% 10.8% 11.7%	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup 1.2.1 Han Chinese i XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z = 1.2.2 Caucasian	CC Events 3 3 1 9 16 58, df = 3 ((= 3.27 (P =	= 2.03. Total 6 4 5 36 51 P = 0.4 = 0.001	TT+ Events 35 37 30 11 113 4); ² = 0)	CT 5 Tota 5 258 5 90 113 142 603 5 %	Weight 3 4.2% 4 10.8% 10.8% 17.7% 3 36.9%	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82]	Favours [experimental] Favours [cont Odds Ratio	10 .rol]
Test for overall effect: Z = Test for subgroup 1.2.1 Han Chinese Li XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z = 1.2.2 Caucasian Malek LA 2008	nces: Chi ² : CC <u>Events</u> 3 3 1 9 16 58, df = 3 ((= 3.27 (P =	= 2.03. <u>Total</u> 6 4 5 36 51 P = 0.4 = 0.001 4	TT+ Events 35 37 30 11 113 113 (4); I ² = 0	CT 5 Tota 6 258 90 113 142 603 6 %	Weight 4.2% 4.2% 10.8% 17.7% 36.9% 2.9%	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82] 1.63 [0.08, 33.71]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup 1.2.1 Han Chinese i XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z = 1.2.2 Caucasian	CC Events 3 3 1 9 16 58, df = 3 ((= 3.27 (P =	= 2.03. <u>Total</u> 6 4 5 36 51 P = 0.4 = 0.001 4 73	TT+ Events 35 37 30 11 113 (4); I ² = 0) (4); I ² = 0	CT 5 Tota 6 258 90 113 142 603 6 % 101 1819	Weight 4.2% 10.8% 17.7% 36.9% 2.9% 55.1%	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82] 1.63 [0.08, 33.71]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup 1.2.1 Han Chinese Li XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z = 1.2.2 Caucasian Malek LA 2008	nces: Chi ² : CC <u>Events</u> 3 3 1 9 16 58, df = 3 ((= 3.27 (P =	= 2.03. Total 6 4 5 36 51 P = 0.4 = 0.001 4 73 7	TT+ Events 35 37 30 11 113 (4); I ² = 0) (4); I ² = 0	CT 5 Tota 5 258 5 90 113 142 603 5 % 5 101 1819 1354	 Weight 4.2% 4.2% 10.8% 17.7% 36.9% 2.9% 55.1% 5.1% 	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82] 1.63 [0.08, 33.71]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subaroup differer Study or Subgroup 1.2.1 Han Chinese Li XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Fest for overall effect: Z = 1.2.2 Caucasian Malek LA 2008 Rudez G 2008	CC Events 3 3 1 9 16 58, df = 3 (f = 3.27 (P = 0 8	= 2.03. <u>Total</u> 6 4 5 36 51 P = 0.4 = 0.001 4 73	TT+ Events 35 37 30 11 113 (4); I ² = 0) (4); I ² = 0	CT 5 Tota 6 258 90 113 142 603 6 % 101 1819	 Weight 4.2% 4.2% 10.8% 17.7% 36.9% 2.9% 55.1% 5.1% 	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82] 1.63 [0.08, 33.71] 1.36 [0.64, 2.89] 1.90 [0.23, 15.96]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subaroup differer Study or Subgroup 1.2.1 Han Chinese Li XQ 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z = 1.2.2 Caucasian Malek LA 2008 Rudez G 2008 /iviani Anselmi C 2013	CC Events 3 3 1 9 16 58, df = 3 (f = 3.27 (P = 0 8	= 2.03. Total 6 4 5 36 51 P = 0.4 = 0.001 4 73 7	TT+ Events 35 37 30 11 113 (4); I ² = 0) (4); I ² = 0	CT 5 Tota 5 258 5 90 113 142 603 5 % 5 101 1819 1354 3274	 Weight 4.2% 4.2% 10.8% 17.7% 36.9% 2.9% 55.1% 5.1% 	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82] 1.63 [0.08, 33.71] 1.36 [0.64, 2.89] 1.90 [0.23, 15.96]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subaroup differer Study or Subgroup 1.2.1 Han Chinese Li XQ 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z = 1.2.2 Caucasian Malek LA 2008 Rudez G 2008 Viviani Anselmi C 2013 Subtotal (95% CI)	nces: Chi ² : CC Events 3 3 1 9 16 58, df = 3 (i = 3.27 (P = 0 8 1 9	= 2.03. <u>Total</u> 6 4 5 36 51 P = 0.4 7 84	TT+ Events 35 37 30 11 113 (4); I ² = 0) (4); I ² = 0) (5) 151 109 266	CT 5 Tota 9 (0 113 142 603 5 % 5 101 1819 1354 3274 5	 Weight 4.2% 4.2% 10.8% 17.7% 36.9% 2.9% 55.1% 5.1% 	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82] 1.63 [0.08, 33.71] 1.36 [0.64, 2.89] 1.90 [0.23, 15.96]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup differer Study or Subgroup 1.2.1 Han Chinese Li XQ 2016 Sub 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z = 1.2.2 Caucasian Malek LA 2008 Rudez G 2008 Viviani Anselmi C 2013 Subtotal (95% CI) Total events	CC Events 3 3 1 9 68, df = 3 ((= 3.27 (P = 0 8 1 9 9 9, df = 2 (1	= 2.03. Total 6 4 5 36 51 P = 0.4 7 84 P = 0.9 P = 0.9	TT+ Events 35 37 30 11 113 (4); I ² = 0) (4); I ² = 0) (5) 151 109 266	CT 5 Tota 9 (0 113 142 603 5 % 5 101 1819 1354 3274 5	 Weight 4.2% 4.2% 10.8% 17.7% 36.9% 2.9% 55.1% 5.1% 	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82] 1.63 [0.08, 33.71] 1.36 [0.64, 2.89] 1.90 [0.23, 15.96]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup L2.1 Han Chinese i XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z = L2.2 Caucasian Malek LA 2008 Rudez G 2008 Viviani Anselmi C 2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.0 Total events Heterogeneity: Chi ² = 0.0 Test for overall effect: Z =	CC Events 3 3 1 9 68, df = 3 ((= 3.27 (P = 0 8 1 9 9 9, df = 2 (1	= 2.03. Total 6 4 5 36 51 P = 0.4 7 7 84 P = 0.9 € 0.32)	TT+ Events 35 37 30 11 113 (4); I ² = 0) (4); I ² = 0) (5) 151 109 266	CT 5 Tota 9 (0) 113 142 603 3 % 101 1819 3274 5 %	 Weight 4.2% 4.2% 10.8% 17.7% 36.9% 55.1% 5.1% 5.1% 63.1% 	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82] 1.63 [0.08, 33.71] 1.36 [0.64, 2.89] 1.90 [0.23, 15.96] 1.42 [0.71, 2.83]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup L2.1 Han Chinese L3.2 Han Chinese L3.2 U Han Chinese L3.2 U 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z = L2.2 Caucasian Malek LA 2008 Rudez G 2008 Viviani Anselmi C 2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.0 Total effect: Z = Total (95% CI)	CC Events 3 3 1 9 58, df = 3 ((= 3.27 (P = 0 8 1 9 9)9, df = 2 ((= 0.99 (P =	= 2.03. Total 6 4 5 36 51 P = 0.4 7 84 P = 0.9 P = 0.9	TT+ Events 35 37 30 11 113 4); ² = 0) 6 151 109 266 5); ² = 0	CT 5 Tota 5 258 5 90 113 142 603 5 % 5 101 1819 1354 3274 5 % 3877	 Weight 4.2% 4.2% 10.8% 17.7% 36.9% 2.9% 55.1% 5.1% 	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82] 1.63 [0.08, 33.71] 1.36 [0.64, 2.89] 1.90 [0.23, 15.96] 1.42 [0.71, 2.83]	Favours [experimental] Favours [cont Odds Ratio	
Test for overall effect: Z = Test for subgroup L2.1 Han Chinese i XQ 2016 Du W 2016 Sun B 2015 Yang HH 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2.6 Test for overall effect: Z = L2.2 Caucasian Malek LA 2008 Rudez G 2008 Viviani Anselmi C 2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.0 Total events Heterogeneity: Chi ² = 0.0 Test for overall effect: Z =	nces: Chi ² : CC Events 3 3 1 9 16 68, df = 3 ((= 3.27 (P = 0 8 1 9 9, df = 2 ((= 0.99 (P = 25	= 2.03. Total 6 4 5 36 51 P = 0.4 7 84 P = 0.9 € 0.32) 135	TT+ Events 35 37 30 11 113 4); ² = 0) 6 151 109 266 5; ² = 0 379	CT 5 Tota 9 (0) 113 142 603 3 % 101 1819 1354 3274 3 % 3877	 Weight 4.2% 4.2% 10.8% 17.7% 36.9% 55.1% 5.1% 5.1% 63.1% 	% Odds Ratio M-H. Fixed. 95% Cl 6.37 [1.24, 32.83] 4.30 [0.43, 42.94] 0.69 [0.07, 6.44] 3.97 [1.50, 10.51] 3.32 [1.62, 6.82] 1.63 [0.08, 33.71] 1.36 [0.64, 2.89] 1.90 [0.23, 15.96] 1.42 [0.71, 2.83]	Favours [experimental] Favours [cont Odds Ratio	

▶ Fig. 1 Meta-analysis of the P2Y12 T744C polymorphism and ischemic events under two genotype genetic models. a: CC+CT vs TT model; b: CC vs TT+CT model.

TT + CT), seven studies including 4,012 patients were analyzed. The heterogeneity test was performed in two different genotype genetic models (CC + CT vs TT: P=0.03, I²=54% and CC vs TT + CT: P=0.42, I²=1%), and the random-effects model and the fixed-effects model was respectively used for this analysis (**▶ Fig. 1**). In the analysis of CC + CT vs TT genetic model, no significant association was found between the P2Y12 T744C polymorphism and ischemic events either in the Han Chinese population (OR=1.59, 95%CI=0.88-2.84, P=0.12) or in the Caucasian population (OR = 0.99, 95 %CI = 0.75-1.31, P = 0.95). However, in another analysis of CC vs TT + CT genetic model, the correlation between the P2Y12 T744C polymorphism and ischemic events was significant in the Han Chinese population (OR = 3.32, 95 %CI = 1.62-6.82, P = 0.001), but it was not significant in the Caucasian population (OR = 1.42, 95 %CI = 0.71-2.83, P = 0.32).

¥	Thieme
---	--------

	TT+T	-	GG			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
2.1.1 Han Chinese							
Li MN 2017	22	102	49	396	11.4%	1.95 [1.11, 3.40]	
Lin YJ 2014	3	28	12	62	4.8%	0.50 [0.13, 1.93]	
Ou W 2016	9	26	31	68	8.1%	0.63 [0.25, 1.61]	
Zhang JH 2015	6	102	28	399	7.8%	0.83 [0.33, 2.06]	
Subtotal (95% CI)		258		925	32.1%	1.13 [0.76, 1.68]	
Total events	40		120				
Heterogeneity: Chi ² = 6		•		57%			
Test for overall effect:	Z = 0.58 (I	P = 0.56	3)				
2.1.2 Caucasian							
Simon T 2009	89	607	194	1537	67.9%	1.19 [0.91, 1.56]	H
Subtotal (95% CI)		607		1537	67.9%	1.19 [0.91, 1.56]	•
Total events	89		194				
Heterogeneity: Not app							
Test for overall effect:		P = 0.21)				
		0.2	,				
Total (95% CI)		865		2462	100.0%	1.17 [0.93, 1.46]	◆
Total events	129		314				
Heterogeneity: Chi ² = 6	5.94, df = 4	4 (P = 0	.14); I² =	42%		H	
Test for overall effect:	Z = 1.37 (I	P = 0.17	7)			0.01	0.1 1 10 10
T				(D – 0	00) 12 - 0	ev F	avours [experimental] Favours [control]
Test for subaroup diffe	rences: C	ni² = 0.0	15. at = 1	(P = 0)	.83). 1- = 0	70	
lest for subaroud diffe	rences: C	ni² = 0.(15. at = 1	(P = 0)	.83). 1- = 0	%	
l est for subaroup diffe		nı² = ().(.831. 1* = 0	70	
Test for subaroup diffe	тт		GG+1	ſG		Odds Ratio M-H. Fixed, 95% Cl	Odds Ratio M-H, Fixed, 95% Cl
	тт		GG+1	ſG		Odds Ratio	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese	TT Events	Total	GG+1 Events	rG Total	Weight	Odds Ratio M-H. Fixed, 95% Cl	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014	TT Events 0	<u>Total</u> 4	GG+1 Events	r G Total 86	Weight 9.6%	Odds Ratio <u>M-H. Fixed, 95% Cl</u> 0.51 [0.03, 10.02]	Odds Ratio
<u>Study or Subgroup</u> 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016	TT Events	Total 4 2	GG+1 Events	FG Total 86 92	Weight 9.6% 2.6%	Odds Ratio <u>M-H. Fixed. 95% Cl</u> 0.51 [0.03, 10.02] 7.08 [0.33, 151.60]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015	TT Events 0 2	<u>Total</u> 4	GG+ 1 <u>Events</u> 15 38	r G Total 86	Weight 9.6%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI)	TT Events 0 2 2	Total 4 2 15	GG+1 Events 15 38 32	T G Total 86 92 486	<u>Weight</u> 9.6% 2.6% 10.6%	Odds Ratio <u>M-H. Fixed. 95% Cl</u> 0.51 [0.03, 10.02] 7.08 [0.33, 151.60]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events	TT Events 0 2 2 4	Total 4 2 15 21	GG+1 Events 15 38 32 85	rG Total 86 92 486 664	<u>Weight</u> 9.6% 2.6% 10.6%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 1	TT <u>Events</u> 0 2 2 4 1.47, df = 2	<u>Total</u> 4 2 15 21 2 (P = 0	GG+1 Events 15 38 32 85 .48); I ² =	rG Total 86 92 486 664	<u>Weight</u> 9.6% 2.6% 10.6%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events	TT <u>Events</u> 0 2 2 4 1.47, df = 2	<u>Total</u> 4 2 15 21 2 (P = 0	GG+1 Events 15 38 32 85 .48); I ² =	rG Total 86 92 486 664	<u>Weight</u> 9.6% 2.6% 10.6%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 1	TT <u>Events</u> 0 2 2 4 1.47, df = 2	<u>Total</u> 4 2 15 21 2 (P = 0	GG+1 Events 15 38 32 85 .48); I ² =	rG Total 86 92 486 664	<u>Weight</u> 9.6% 2.6% 10.6%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = - Test for overall effect:	TT <u>Events</u> 0 2 2 4 1.47, df = 2	Total 4 2 15 21 2 (P = 0 P = 0.22 53	GG+1 <u>Events</u> 15 38 32 85 .48); I ² =	rG Total 86 92 486 664	<u>Weight</u> 9.6% 2.6% 10.6%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: 2 2.2.2 Caucasian	TT <u>Events</u> 0 2 2 4 1.47, df = : Z = 1.22 (l	Total 4 2 15 21 2 (P = 0 P = 0.22	GG+1 <u>Events</u> 15 38 32 85 .48); I ² =	TG Total 86 92 486 664 0%	9.6% 2.6% 10.6% 22.8%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09] 2.02 [0.65, 6.28]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = - Test for overall effect: : 2.2.2 Caucasian Simon T 2009	TT <u>Events</u> 0 2 2 4 1.47, df = : Z = 1.22 (l	Total 4 2 15 21 2 (P = 0 P = 0.22 53	GG+1 <u>Events</u> 15 38 32 85 .48); I ² =	TG Total 86 92 486 664 0% 2091	Weight 9.6% 2.6% 10.6% 22.8%	Odds Ratio <u>M-H, Fixed. 95% Cl</u> 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09] 2.02 [0.65, 6.28] 0.84 [0.35, 1.97]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 7 Test for overall effect: 2.2.2 Caucasian Simon T 2009 Subtotal (95% Cl) Total events	TT Events 0 2 2 4 1.47, df = 2 Z = 1.22 (f 6 6	Total 4 2 15 21 2 (P = 0 P = 0.22 53	GG+1 Events 15 38 32 85 .48); ² = 2) 277	TG Total 86 92 486 664 0% 2091	Weight 9.6% 2.6% 10.6% 22.8%	Odds Ratio <u>M-H, Fixed. 95% Cl</u> 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09] 2.02 [0.65, 6.28] 0.84 [0.35, 1.97]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: 2.2.2 Caucasian Simon T 2009 Subtotal (95% Cl)	TT Events 0 2 2 4 1.47, df = 2 Z = 1.22 (1 6 6 6 0licable	Total 4 2 15 21 2 (P = 0 P = 0.22 53 53	GG+1 Events 15 38 32 85 .48); I ² = 2) 277 277	TG Total 86 92 486 664 0% 2091	Weight 9.6% 2.6% 10.6% 22.8%	Odds Ratio <u>M-H, Fixed. 95% Cl</u> 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09] 2.02 [0.65, 6.28] 0.84 [0.35, 1.97]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 1 2.2.2 Caucasian Simon T 2009 Subtotal (95% Cl) Total events Heterogeneity: Not app Test for overall effect: 1	TT Events 0 2 2 4 1.47, df = 2 Z = 1.22 (1 6 6 6 0licable	$ \begin{array}{r} 4 \\ 2 \\ 15 \\ 21 \\ 2 (P = 0) \\ P = 0.22 \\ 53 \\ 53 \\ 53 \\ P = 0.68 \\ $	GG+1 Events 15 38 32 85 .48); I ² = 2) 277 277	rG Total 86 92 486 664 0% 2091 2091	Weight 9.6% 2.6% 10.6% 22.8% 77.2% 77.2%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09] 2.02 [0.65, 6.28] 0.84 [0.35, 1.97] 0.84 [0.35, 1.97]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = - 2.2.2 Caucasian Simon T 2009 Subtotal (95% Cl) Total events Heterogeneity: Not app Test for overall effect: - Total (95% Cl)	TT Events 0 2 2 4 1.47, df = 2 Z = 1.22 (I 6 6 6 6 6 6 6 6 6 6 6 1.22 (I 2 1.22 (I 6 6 6 7 1.22 (I 1.22 (I 1.2	Total 4 2 15 21 2 (P = 0 P = 0.22 53 53	GG+1 <u>Events</u> 15 38 32 85 .48); I ² = 277 277 277 3)	rG Total 86 92 486 664 0% 2091 2091	Weight 9.6% 2.6% 10.6% 22.8%	Odds Ratio <u>M-H, Fixed. 95% Cl</u> 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09] 2.02 [0.65, 6.28] 0.84 [0.35, 1.97]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 1 2.2.2 Caucasian Simon T 2009 Subtotal (95% Cl) Total events Heterogeneity: Not app Test for overall effect: 1 Total (95% Cl) Total events	TT Events 0 2 2 4 1.47, df = : Z = 1.22 (I 6 6 6 6 6 6 6 6 6 6 6 6 6	$ \begin{array}{r} 4 \\ 2 \\ 15 \\ 21 \\ 2 (P = 0) \\ P = 0.22 \\ 53 \\ 53 \\ 53 \\ P = 0.68 \\ 74 \\ 74 $	GG+1 <u>Events</u> 15 38 32 85 .48); I ² = 277 277 277 3) 362	rG Total 86 92 486 664 0% 2091 2091 2091	Weight 9.6% 2.6% 10.6% 22.8% 77.2% 77.2%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09] 2.02 [0.65, 6.28] 0.84 [0.35, 1.97] 0.84 [0.35, 1.97]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 1 2.2.2 Caucasian Simon T 2009 Subtotal (95% Cl) Total events Heterogeneity: Not app Test for overall effect: Total (95% Cl) Total events Heterogeneity: Chi ² = 2	TT Events 0 2 2 4 1.47, df = ; Z = 1.22 (l 6 blicable Z = 0.41 (l 10 2.83, df = ;	$\begin{array}{c} Total \\ 4 \\ 2 \\ $	GG+1 <u>Events</u> 15 38 32 85 .48); I ² = 277 277 277 3) 362 .42); I ² =	rG Total 86 92 486 664 0% 2091 2091 2091	Weight 9.6% 2.6% 10.6% 22.8% 77.2% 77.2%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09] 2.02 [0.65, 6.28] 0.84 [0.35, 1.97] 0.84 [0.35, 1.97]	Odds Ratio
Study or Subgroup 2.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = - 2.2.2 Caucasian Simon T 2009 Subtotal (95% CI) Total events Heterogeneity: Not app Test for overall effect: - Total (95% CI) Total events	TT Events 0 2 2 4 1.47, df = : Z = 1.22 (l 6 6 6 6 6 6 6 6 6 6 6 2 2 = 0.41 (l 2 2 2 4 1.42, df = : 2 2 4 1.42, df = : 2 2 4 1.42, df = : 2 1.22 (l 6 6 6 2 2 1.22 (l 6 2 2 1.22 (l 6 2 2 1.22 (l 6 2 2 1.22 (l 6 2 2 1.22 (l 6 2 2 1.22 (l 7 1.22	$\begin{array}{c} $	GG+1 <u>Events</u> 15 38 32 85 .48); I ² = 277 277 277 3) 362 .42); I ² = 7)	rG Total 86 92 486 664 0% 2091 2091 2091 2091 2095	Weight 9.6% 2.6% 10.6% 22.8% 77.2% 77.2%	Odds Ratio M-H. Fixed. 95% Cl 0.51 [0.03, 10.02] 7.08 [0.33, 151.60] 2.18 [0.47, 10.09] 2.02 [0.65, 6.28] 0.84 [0.35, 1.97] 0.84 [0.35, 1.97] 1.11 [0.57, 2.16]	Odds Ratio M-H, Fixed, 95% Cl

Fig. 2 Meta-analysis of the P2Y12 G52T polymorphism and ischemic events under two genotype genetic models. **a**: TT + TG vs GG model; **b**: TT vs GG + TG model.

Association of the P2Y12 G52T polymorphism with ischemic events.

Five studies reported an association of the P2Y12 G52T polymorphism with adverse clinical outcomes. Only one study was conducted in the Caucasian population, and the other four studies were in the Han Chinese population. Of the 3327 subjects, 443 had ischemic events, and 865 were carriers of the T allele in the TT + TG vs GG genetic model. However, four studies with complete data were enrolled in another genetic model, including a total of 2,829 subjects. The fixed-effects model was performed because a lower heterogeneity was identified ($I^2 = 42\%$ and $I^2 = 0\%$) in different genotype ge-

netic models (▶ **Fig. 2**). The analysis indicated that ischemic events were not associated with the P2Y12 G52T polymorphism (TT + TG vs GG: OR = 1.13, 95 %CI = 0.76-1.68, P = 0.56; TT vs GG + TG: OR = 2.02, 95 %CI = 0.65-6.28, P = 0.22) in the Han Chinese population.

Association of the P2Y12 C34T polymorphism with ischemic events

Seven studies reporting an association of the P2Y12 C34T polymorphism with ischemic events were included. A total of 4,176 patients were recruited in the TT + TC vs CC genetic model, while only four studies provided complete information in the TT vs CC + TC genet-


Church and Curch and and	TT+T	-	CC	Tatal	Malakt	Odds Ratio	Odds Ratio
Study or Subgroup 3.1.1 Han Chinese	Events	Total	Events	Total	Weight	<u>M-H. Random, 95% CI</u>	M-H. Random, 95% Cl
Li MN 2017	34	174	37	324	18.4%	1.88 [1.13, 3.13]	
Lin YJ 2014	5	32	10	58	6.7%	0.89 [0.28, 2.87]	
Ou W 2016	14	31	26	63	10.4%	1.17 [0.49, 2.79]	
Tang XF 2013	13	220	9	357	10.4%	2.43 [1.02, 5.78]	
Zhang JH 2015 Subtotal (95% CI)	19	215 672	15	288 1090	13.4% 59.2%	1.76 [0.87, 3.56] 1.70 [1.22, 2.36]	•
Total events	85		97				
Heterogeneity: Tau ² = Test for overall effect: 2	,			9 = 0.61); I ² = 0%		
3.1.2 Caucasian							
Siasos G 2016	25	124	18	105	14.1%	1.22 [0.62, 2.39]	
Simon T 2009	138	1107	150	1078	26.6%	0.88 [0.69, 1.13]	1
Subtotal (95% CI)		1231		1183	40.8%	0.92 [0.73, 1.16]	₹
Total events	163		168				
Heterogeneity: Tau ² = Test for overall effect: 3				9 = 0.37	'); I² = 0%		
Total (95% CI)		1903		2273	100.0%	1.33 [0.95, 1.88]	◆
			265				
	248						
Heterogeneity: Tau ² =	0.10; Chi ²		2, df = 6 (P = 0.0	95); I² = 52%	6	
Total events Heterogeneity: Tau ² = Test for overall effect: <i>i</i> Test for subaroup diffe	0.10; Chi² Z = 1.65 (F	P = 0.10	2, df = 6 (0)			0	LO1 0.1 1 10 10 Favours [experimental] Favours [control]
Heterogeneity: Tau² = Test for overall effect: . Test for subarouo diffe	0.10; Chi² Z = 1.65 (F rences: Cl TT	P = 0.10 hi ² = 9.0	2, df = 6 (0) 02. df = 1 CC+	(P = 0. TC	003). I² = 8	0 8.9% Odds Ratio	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: . Test for subarouo diffe Study or Subgroup	0.10; Chi² Z = 1.65 (F rences: Cl TT	P = 0.10 hi ² = 9.0	2, df = 6 (0) 02. df = 1 CC+	(P = 0. TC	003). I² = 8	0 8.9%	Favours [experimental] Favours [control]
Heterogeneity: Tau ² = Test for overall effect: : Test for subaroup diffe Study or Subgroup 3.2.1 Han Chinese	0.10; Chi ² Z = 1.65 (F rences: Cl TT <u>Events</u>	P = 0.10 hi ² = 9.0 Total	2, df = 6 (0) 02. df = 1 CC+ Events	(P = 0. TC <u>Tota</u>	003). I² = 8 I Weight	0 88.9% Odds Ratio <u>M-H. Fixed. 95% Cl</u>	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: : Test for subarouo diffe Study or Subgroup 3.2.1 Han Chinese Lin YJ 2014	0.10; Chi ² Z = 1.65 (F rences: Cl TT <u>Events</u> 0	P = 0.10 hi ² = 9.0 Total 5	2, df = 6 (0) 02. df = 1 CC+ <u>Events</u> 15	(P = 0. TC Tota 85	003). I ² = 8 I <u>Weight</u> 5 3.5%	0 88.9% Odds Ratio <u>M-H. Fixed. 95% Cl</u> 0.41 [0.02, 7.87]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: : Test for subaroup diffe Study or Subgroup 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016	0.10; Chi ² Z = 1.65 (F rences: Cl TT <u>Events</u> 0 4	² = 0.10 hi ² = 9.0 <u>Total</u> 5 5	2, df = 6 (0) 02. df = 1 CC+ <u>Events</u> 15 36	(P = 0. TC Tota 85 89	003). I ² = 8 I Weight 5 3.5% 9 1.4%	0 88.9% Odds Ratio <u>M-H. Fixed. 95% Cl</u> 0.41 [0.02, 7.87] 5.89 [0.63, 54.87]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: . Test for subaroup diffe Study or Subgroup 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015	0.10; Chi ² Z = 1.65 (F rences: Cl TT <u>Events</u> 0	² = 0.10 hi ² = 9.0 Total 5 5 30	2, df = 6 (0) 02. df = 1 CC+ <u>Events</u> 15 36	(P = 0. TC Tota 85 89 473	003). I ² = 8 Weight 3.5% 1.4% 6.7%	0 0dds Ratio <u>M-H. Fixed. 95% Cl</u> 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: : Test for subarouo diffe 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI)	0.10; Chi ² Z = 1.65 (F rences: Cl TT <u>Events</u> 0 4 2	² = 0.10 hi ² = 9.0 <u>Total</u> 5 5	2, df = 6 ()))2. df = 1 CC+ Events 15 36 32	(P = 0. TC <u>Tota</u> 85 89 473 647	003). I ² = 8 Weight 3.5% 1.4% 6.7%	0 88.9% Odds Ratio <u>M-H. Fixed. 95% Cl</u> 0.41 [0.02, 7.87] 5.89 [0.63, 54.87]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: . Test for subarouo diffe 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events	0.10; Chi ² Z = 1.65 (f rences: Cl TT Events 0 4 2 6	² = 0.1(hi ² = 9.0 Total 5 5 30 40	2, df = 6 (0) 02. df = 1 CC+' Events 15 36 32 83	(P = 0. TC Tota 85 89 473 647	003). I ² = 8 Weight 3.5% 1.4% 6.7%	0 0dds Ratio <u>M-H. Fixed. 95% Cl</u> 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: . Test for subaroub diffe Study or Subgroup 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² =	0.10; Chi ² Z = 1.65 (f rences: Cl TT Events 0 4 2 2.47, df =	P = 0.10 hi ² = 9.0 Total 5 5 30 40 2 (P =	2, df = 6 (0) 02. df = 1 CC+' Events 15 36 32 83 0.29); I ² =	(P = 0. TC Tota 85 89 473 647	003). I ² = 8 Weight 3.5% 1.4% 6.7%	0 0dds Ratio <u>M-H. Fixed. 95% Cl</u> 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: . Test for suboroup diffe Study or Subgroup 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect:	0.10; Chi ² Z = 1.65 (f rences: Cl TT Events 0 4 2 2.47, df =	P = 0.10 hi ² = 9.0 Total 5 5 30 40 2 (P =	2, df = 6 (0) 02. df = 1 CC+' Events 15 36 32 83 0.29); I ² =	(P = 0. TC Tota 85 89 473 647	003). I ² = 8 Weight 3.5% 1.4% 6.7%	0 0dds Ratio <u>M-H. Fixed. 95% Cl</u> 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: . Test for suborouo diffe 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 3.2.2 Caucasian Simon T 2009	0.10; Chi ² Z = 1.65 (f rences: Cl TT Events 0 4 2 2.47, df =	P = 0.10 hi ² = 9.0 Total 5 5 30 40 2 (P = P = 0.4 214	2, df = 6 (0) 02. df = 1 CC++ Events 15 36 32 83 0.29); I ² = 18)	(P = 0. TC <u>Tota</u> 85 89 473 647 = 19% 1971	003). ² = 8 Weight 3.5% 1.4% 6.7% 11.7% 88.3%	0 Odds Ratio M-H. Fixed. 95% Cl 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32] 1.42 [0.53, 3.78] 0.73 [0.46, 1.16]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: . Test for suborouo diffe 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 3.2.2 Caucasian Simon T 2009 Subtotal (95% CI)	0.10; Chi ² Z = 1.65 (f rences: Cl TT Events 0 4 2 2 6 2.47, df = Z = 0.70 (22	P = 0.10 hi ² = 9.0 5 5 30 40 2 (P = P = 0.4	2, df = 6 (2) 22. df = 1 CC++ Events 15 36 32 83 0.29); ² = 18) 266	(P = 0. TC 5 Tota 85 89 473 647 = 19% 1971 1971	003). ² = 8 Weight 3.5% 1.4% 6.7% 11.7% 88.3%	0 Odds Ratio M-H. Fixed. 95% Cl 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32] 1.42 [0.53, 3.78]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: . Test for suborouo diffe 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 3.2.2 Caucasian Simon T 2009 Subtotal (95% CI) Total events	0.10; Chi ² Z = 1.65 (f rences: Cl TT Events 0 4 2.47, df = Z = 0.70 (22 22	P = 0.10 hi ² = 9.0 Total 5 5 30 40 2 (P = P = 0.4 214	2, df = 6 (0) 02. df = 1 CC++ Events 15 36 32 83 0.29); I ² = 18)	(P = 0. TC 5 Tota 85 89 473 647 = 19% 1971 1971	003). ² = 8 Weight 3.5% 1.4% 6.7% 11.7% 88.3%	0 Odds Ratio M-H. Fixed. 95% Cl 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32] 1.42 [0.53, 3.78] 0.73 [0.46, 1.16]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: . Test for suborouo diffe 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 3.2.2 Caucasian Simon T 2009 Subtotal (95% CI) Total events Heterogeneity: Not ap	0.10; Chi ² Z = 1.65 (f rences: Cl TT Events 0 4 2.47, df = Z = 0.70 (22 22 plicable	P = 0.10 hi ² = 9.0 Total 5 30 40 2 (P = P = 0.4 214 214	2, df = 6 (2) 22. df = 1 CC++ Events 15 36 32 83 0.29); l ² = 18) 266 266	(P = 0. TC 5 Tota 85 89 473 647 = 19% 1971 1971	003). ² = 8 Weight 3.5% 1.4% 6.7% 11.7% 88.3%	0 Odds Ratio M-H. Fixed. 95% Cl 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32] 1.42 [0.53, 3.78] 0.73 [0.46, 1.16]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: : Test for suborouo diffe 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 3.2.2 Caucasian Simon T 2009 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect:	0.10; Chi ² Z = 1.65 (f rences: Cl TT Events 0 4 2.47, df = Z = 0.70 (22 22 plicable	P = 0.10 hi ² = 9.0 Total 5 30 40 2 (P = P = 0.4 214 214	2, df = 6 (2) 22. df = 1 CC++ Events 15 36 32 83 0.29); l ² = 18) 266 266	(P = 0. TC Tota 85 473 647 = 19% 1971	003). ² = 8 Weight 3.5% 1.4% 6.7% 11.7% 88.3%	0 Odds Ratio M-H. Fixed. 95% Cl 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32] 1.42 [0.53, 3.78] 0.73 [0.46, 1.16]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: : Test for suborouo diffe 3.2.1 Han Chinese Lin YJ 2014 Ou W 2016 Zhang JH 2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 3.2.2 Caucasian Simon T 2009 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect: Total (95% CI)	0.10; Chi ² Z = 1.65 (f rences: Cl TT Events 0 4 2.47, df = Z = 0.70 (22 22 plicable	P = 0.10 hi ² = 9.0 Total 5 5 30 40 2 (P = P = 0.4 214 214 P = 0.1	2, df = 6 (2) 22. df = 1 CC++ Events 15 36 32 83 0.29); l ² = 18) 266 266	(P = 0. TC Tota 85 473 647 = 19% 1971 1971 2618	003). ² = 8 Weight 3.5% 1.4% 6.7% 11.7% 88.3% 88.3%	0 0dds Ratio <u>M-H. Fixed. 95% Cl</u> 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32] 1.42 [0.53, 3.78] 0.73 [0.46, 1.16] 0.73 [0.46, 1.16]	Favours [experimental] Favours [control] Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: 2	0.10; Chi ² Z = 1.65 (F rences: Cl TT Events 0 4 2.47, df = Z = 0.70 (22 plicable Z = 1.32 (28	P = 0.10 $hi^2 = 9.0$ Total 5 30 40 2 (P = P = 0.4 214 214 P = 0.1 254	2, df = 6 (2) 22. df = 1 CC+ ⁺ Events 15 36 32 83 0.29); l ² = 18) 266 266 19) 349	(P = 0. TC Tota 89 473 647 = 19% 1971 1971 2618	003). ² = 8 Weight 3.5% 1.4% 6.7% 11.7% 88.3% 88.3%	0 0dds Ratio <u>M-H. Fixed. 95% Cl</u> 0.41 [0.02, 7.87] 5.89 [0.63, 54.87] 0.98 [0.22, 4.32] 1.42 [0.53, 3.78] 0.73 [0.46, 1.16] 0.73 [0.46, 1.16]	Favours [experimental] Favours [control]

▶ Fig. 3 Meta-analysis of the P2Y12 C34T polymorphism and ischemic events under two genotype genetic models. a: TT + TC vs CC model; b: TT vs CC + TC model.

ic model. The fixed-effects model and the random-effects model were adopted respectively after heterogeneity testing (▶ Fig. 3). In the Han Chinese population, a significant association between the P2Y12 C34T polymorphism and ischemic events was found under the TT+TC vs CC genetic model (OR = 1.70, 95%CI = 1.22-2.36, P=0.002). However, the association was not found in the Caucasian population (OR = 0.92, 95%CI = 0.73-1.16, P = 0.46). Meanwhile, the P2Y12 C34T polymorphism was unrelated to ischemic events under the TT vs CC+TC genetic model in both populations.

Association of the P2Y12 C34T polymorphism with bleeding events

Two studies referring to bleeding events were included in the analysis of the C34T polymorphism. The association of the P2Y12 C34T polymorphism with bleeding events was analyzed under the TT + TC vs CC genetic model. The random-effects model was chosen on the basis of a higher heterogeneity ($I^2 = 82\%$, **Fig. 4**). No significant association was found in this analysis (OR = 1.07, 95%CI = 0.37-3.15, P = 0.90).



▶ Fig. 4 Meta-analysis of the P2Y12 C34T polymorphism and bleeding events under the TT+TC vs CC model.

► **Table 1** Sensitivity analysis of the P2Y12 T744C polymorphism and ischemic events in the Han Chinese population.

CC+C	۲ vs TT	CC vs TT+CT							
Study Exclusion	RE (<i>P</i> value)	Study Exclusion	FE (P value)						
Li XQ 2016	0.31	Li XQ 2016	0.008						
Ou W 2016	0.008	Ou W 2016	0.003						
Sun B 2015	0.08	Sun B 2015	0.0003						
Wang XD 2016	0.38	1	1						
Yang HH 2016	0.32	Yang HH 2016	0.07						
FE: fixed-effects	FE: fixed-effects model, RE: random-effects model.								

Sensitivity analysis

Sensitivity analysis was performed by the exclusion of a single study in turn. In this analysis of the Han Chinese population on the P2Y12 T744C polymorphism, the pooled P-values changed respectively when Ou W[33] was excluded under the CC + CT vs TT genetic model and when Yang HH[32] was excluded under the CC vs TT + CT genetic model. However, no other single study could influence the pooled P-values in the remaining exclusion analyses (**▶ Table 1**).

Publication bias

The publication bias was evaluated by funnel plots, and the shapes were symmetrical, suggesting no publication bias among these analyses (**Supporting Material 3**). The funnel plot of bleeding events was not performed because only two studies were included.

Discussion

Clopidogrel is a thienopyridine derivative inhibiting ADP-mediated platelet aggregation[35]. The active metabolite binds irreversibly and specifically to the P2Y12 platelet receptor. An individual variability is observed in patients receiving clopidogrel treatment, and some patients can experience adverse clinical events[4]. Clopidogrel poor response is likely caused by multiple factors, including genetics, increasing age, greater body mass index (BMI), higher triglyceride levels and lower levels of high-density lipoprotein cholesterol[36, 37].

The P2Y12 gene is located in the q25.1 region of chromosome 3, and it belongs to the G-protein coupled receptor family. The coupling of the P2Y12 protein with the inhibitory G alpha protein subunit results in the inhibition of cyclic adenosine monophosphate (cAMP) production, and therefore a subsequent reduction in the intracellular cAMP content. Furthermore, P2Y12 receptor induces a platelet aggregation through a weak activation of glycoprotein IIb/IIIa integrin via the phosphoinositide kinase-3 pathway [7]. Platelet activation by ADP plays a crucial role in hemostasis and thrombosis. Numerous studies have established the key role of this receptor in the ADP-dependent amplification of platelet aggregation induced by other agonists, such as thromboxane A2 and thrombin [38, 39]. The antithrombotic effect of clopidogrel and the ADP-induced platelet response are considerably variable. Therefore, the P2Y12 gene is screened for possible variants.

Many studies investigated the relationship of the P2Y12 gene polymorphism and adverse clinical events, but these studies[8, 9, 22–34] had divergent results. It is therefore necessary to perform a meta-analysis exploring this association. A total of 14 articles were included, and the NOS value of each article is greater than 5. Three genotypes (T744C, G52T and C34T) of the P2Y12 gene were analyzed in our study.

T744C is located at the 744 nucleotide after the 5' intron start site and consists of a T-to-C transition [7]. Both C34T and G52T are located in the coding region of the P2Y12 gene (cds-synon). Fontana P et al. examined ADP-induced platelet aggregation responses in healthy volunteers, and sequence variations in the P2Y12 gene were investigated. They identified two phenotypic groups (haplotypes H1 and H2) of subjects with high and low responsiveness to 2 micromol/L ADP [7]. Four frequent polymorphisms (i-C139T (rs10935838), i-T744C (rs2046934), i-ins801A (rs5853517), G52T (rs6809699)) were in total linkage disequilibrium, determining haplotypes H1 and H2, with respective allelic frequencies of 0.86 and 0.14. The presence of the minor haplotype H2 was associated with an enhanced ADP-induced platelet aggregation in healthy volunteers. The molecular mechanism by which the H2 haplotype increases ADP-induced platelet aggregation remains unclear. Based on the investigated sequence, an amino acid substitution affecting the protein structure or splice variants could be ruled out. Thus, an increase in the number of platelet surface receptors is most likely the explanation [7]. C34T is not part of the haplotype and no function research was found until now.

Based on the analysis of subgroups, significant associations between the P2Y12 T744C/C34T polymorphism and ischemic events were found (P<0.05), but the association of the P2Y12 G52T polymorphism and ischemic events is not observed (P>0.05) in the Han Chinese population. Ischemic events are related to the P2Y12 T744C polymorphism under the CC vs TT + CT genetic model (P=0.001), therefore the T744C genotype may predict the risk of

recurrent ischemic events in the Han Chinese patients. Patients with a mutant homozygote (CC) of the T744C genotype had a higher risk of recurrent ischemic events within one year (OR>1). A total of 7.8% of all enrolled patients were mutant homozygote, and 31.4% of them had recurrent ischemic events. As for the sensitivity analysis, the pooled P values changed when the Ou W[33] study was excluded in the CC + CT vs TT genetic model (P = 0.008), and when Yang HH[32] was excluded in the CC vs TT + CT genetic model (P=0.07). Ou W suggested that T744C variants were not associated with a response to clopidogrel (weight 11.0%), and the incidence of ischemic events was not different between the mutant C allele carriers and non-carriers. Yang HH found that the T744C polymorphism was associated with the efficacy of clopidogrel treatment (i.e. reduction of major adverse cardiac events), and patients carrying the CC genotype were more likely to have ischemic events than other genotypes. Second, ischemic events and the P2Y12 C34T polymorphism are related under the TT + TC vs CC genetic model in the Han Chinese population. P2Y12 C34T polymorphisms may predict the risk of recurrent ischemic events, and carriers of the mutant T allele have a higher risk of composite ischemic events after taking clopidogrel. A total of 38.1% of patients were carriers of the mutant T allele, and 12.6% of them had recurrent ischemic events compared to 8.9% of the non-carriers. According to the sensitivity analysis, the pooled P-values are not significantly affected when each single study is excluded respectively. The results were similar in sensitivity analyses for studies between G52T polymorphism and clinical events. Sionova M et al. investigated the association of P2Y12 polymorphisms (C34T and T744C) with increased risk of peri-procedural bleeding in patients undergoing coronary angiography/PCI. No significant association of the SNPs of P2Y12 C32T and T744C with an increased risk of peri-procedural bleeding was found in their patients[40]. Since the study had a short-term follow-up (30 days), it was excluded from the meta-analysis.

In addition, studies on the P2Y12 gene polymorphism and the incidence of ischemic events in the Caucasian population failed to establish an association. The pooled P-value was not influenced when excluding any single study, revealing that a single study could not change the result of the Caucasian population analysis.

After data on the Han Chinese and the Caucasian populations were merged, there was no significant correlation between the three locus variants and clinical events (ischemia and hemorrhage) after drug administration. However, the subgroup analysis found clinical events were associated with genetic variants (T744C and C34T) in the Han Chinese population but not in Caucasians. We speculate the reasons are as follows: 1) the studies included in this analysis are mostly based on the data within the Chinese population, and there are few reports on the Caucasian population. The smaller sample size of the Caucasian population may lead to biased results; 2) there is a large difference in the frequency of gene mutations between races. The mutation rate of T744C in Chinese population is 16.0%-30.6%, versus 8.7%-19.9% in the Caucasian population. The mutation frequency of C34T in the Chinese population is 20.5%–21.2%, versus around 43.3% in the Caucasian population. The differences in sample size and the different mutation frequencies between races may lead to inconsistencies in study results.

Several limitations in this meta-analysis should be noted: 1) the sample size in these included studies was relatively small, which

may reduce the statistical power, 2) lack of original data in published studies limited further analysis, 3) the majority of the included studies were conducted in Han Chinese patients and Caucasian patients, and further studies are needed from different ethnic groups, and 4) due to inadequate data, certain ischemic events were not predicted, such as TIA, MI, TVR, ST, and other fatal vascular-related events.

Conclusions

The P2Y12 T744C and C34T polymorphisms are found to be associated with ischemic events in Han Chinese patients treated with clopidogrel, and the P2Y12 G52T polymorphism has no significant impact on ischemic events. Patients with the CC homozygote of the T744C genotype have a higher risk of recurrent ischemic events, and the carriers of the mutant T allele of the C34T genotype are more likely than non-carriers to have ischemic events. However, the risk of clinical ischemic events is not related to P2Y12 T744C, G52T and C34T polymorphisms in the Caucasian population. Bleeding events are not significantly associated with the P2Y12 C34T polymorphism in the Han Chinese population. Further research on the relationship of other genetic factors of P2Y12 and the risks of bleeding events in patients treated with clopidogrel is needed.

Authors' contribution

X Li and Z Zhao conceived and designed the study. K Zhao, Ming Yang and S Sun performed the analysis and wrote the manuscript. Y Lu, W Li and Z Zhao supervised the quality of the study. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the National Natural Science Foundation of China [81503157] and the Beijing Municipal Administration of Hospital Mission Plan [QML20170506]. We also thank all the participants in this study.

Conflict of Interest

No conflict of interest has been declared by the author(s).

References

- Tang M, Mukundan M, Yang J et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 2006; 319: 1467–1476
- [2] Wright RS, Anderson JL, Adams CD et al. 2011; ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 2022–2060

- [3] Qiu LN, Sun Y, Wang L et al. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel. Eur J Pharmacol 2015; 747: 29–35
- [4] Yang J, Wang X, Peng L et al. CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients. Int J Cardiol 2015; 189: 225–227
- [5] Bundhun PK, Qin T, Chen MH. Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: A systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2015; 15: 118
- [6] Campo G, Fileti L, Valgimigli M et al. Poor response to clopidogrel: Current and future options for its management. J Thromb Thrombolysis 2010; 30: 319–331
- [7] Fontana P, Dupont A, Gandrille S et al. Adenosine diphosphateinduced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989–995
- [8] Li XQ, Ma N, Li XG et al. Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting. PLoS One 2016; 11: e0148891
- [9] Sun B, Li J, Dong M et al. Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients. Genet Mol Res 2015; 14: 1434–1442
- [10] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–605
- [11] Su J, Xu J, Li X et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: A meta-analysis. PLoS One 2012; 7: e46366
- [12] Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. J Manag Care Spec Pharm 2016; 22: 939–947
- [13] Wen Y, Huang Z, Zhang X et al. Correlation between PON1 gene polymorphisms and breast cancer risk: A Meta-analysis. Int J. Clin Exp Med 2015; 8: 20343–20348
- [14] Ziegler S, Schillinger M, Funk M et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005; 36: 1394–1399
- [15] Wu H, Qian J, Xu J et al. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenet Genomics 2012; 22: 887–890
- [16] Liang ZY, Han YL, Zhang XL et al. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: Outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention 2013; 9: 316–327
- [17] Yi X, Wang Y, Lin J et al. Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. Clin Appl Thromb Hemost 2016
- [18] Bouman HJ, van Werkum JW, Rudez G et al. The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: A clinical follow-up. Thromb Haemost 2012; 107: 189–191
- [19] Siasos G, Oikonomou E, Vavuranakis M et al. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. Cardiology 2017; 137: 104–113
- [20] Smith SM, Judge HM, Peters G et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006; 17: 250–258

- [21] Li XJ, Chen XM. Association between clopidogrel resistance and polymorphism of platelet adenosine diphosphate receptor in patients with coronary atherosclerotic disease. Zhejiang Da Xue Xue Bao Yi Xue Ban 2014; 43: 333–338
- [22] Lin YJ, Li JW, Zhang MJ et al. The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment. CNS Neurosci Ther 2014; 20: 125–130
- [23] Malek LA, Kisiel B, Spiewak M et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008; 72: 1165–1169
- [24] Zhang JH, Wang J, Tang XF et al. Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention. Platelets 2016; 27: 75–79
- [25] Tang XF, Zhang JH, Wang J et al. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl) 2013; 126: 1069–1075
- [26] Sen HM, Silan F, Silan C et al. Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease. Balkan J Med Genet 2014; 17: 37–41
- [27] Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363–375
- [28] Siasos G, Kioufis S, Oikonomou E et al. Impact of C34T P2Y12 ADP receptor polymorphism and smoking status on cardiovascular outcome in coronary artery disease patients receiving clopidogrel. Int J Cardiol 2016; 210: 161–163
- [29] Rudez G, Pons D, Leebeek F et al. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat 2008; 29: 375–380
- [30] Viviani Anselmi C, Briguori C, Roncarati R et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv 2013; 6: 1166–1175
- [31] Li M, Wang H, Xuan L et al. Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. Medicine (Baltimore) 2017; 96: e6553
- [32] Yang HH, Chen Y, Gao CY. Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel. Cardiovasc Ther 2016; 34: 460–467
- [33] Ou W, He Y, Li A et al. Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. Int Heart J 2016; 57: 586–592
- [34] Wang X, Lai Y, Luo Y et al. Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study from Han Chinese. J Res Med Sci 2016; 21: 111
- [35] Li XG, Ma N, Wang B et al. The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease. Sci Rep 2016; 6: 34570
- [36] Shuldiner AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849–857
- [37] Martinelli N, Trabetti E, Pinotti M et al. Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis. PLoS One 2008; 3: e1523

- [38] Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006; 12: 1255–1259
- [39] Haynes SE, Hollopeter G, Yang G et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci 2006; 9: 1512–1519
- [40] Sionova M, Blasko P, Jirous S et al. Association of polymorphisms of platelet receptors GPIa (807C>T), GPVI (13254T>C), and P2Y12 (34C>T and H1/H2 haplotype) with increased risk of periprocedural bleeding in patients undergoing coronary angiography/percutaneous coronary intervention. Postepy Kardiol Interwencyjnej 2017; 13: 202–209